• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ROCHE DIAGNOSTICS ELECSYS ANTI-CCP IMMUNOASSAY; ANTIBODIES, ANTI-CYCLIC CITRULLINATED PEPTIDE (CCP)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ROCHE DIAGNOSTICS ELECSYS ANTI-CCP IMMUNOASSAY; ANTIBODIES, ANTI-CYCLIC CITRULLINATED PEPTIDE (CCP) Back to Search Results
Catalog Number 05031656190
Device Problem Non Reproducible Results (4029)
Patient Problem No Consequences Or Impact To Patient (2199)
Event Date 06/20/2019
Event Type  malfunction  
Manufacturer Narrative
This event occurred in (b)(6).The customer is not having issues with any other assays.Instrument performance testing results were acceptable.
 
Event Description
The initial reporter complained of discrepant results for 1 patient sample tested for elecsys anti-ccp immunoassay (anti-ccp) on a cobas 6000 e 601 module.The initial anti-ccp result was 52.64 u/ml.The customer repeated the sample 19 times until the result was < 7.0 u/ml.No questionable results were reported outside of the laboratory.There was no allegation that an adverse event occurred.The e601 module serial number was (b)(4).
 
Manufacturer Narrative
The following information has been communicated to roche customers: roche has confirmed performance issues with certain lots of the elecsys anti-ccp assay on the cobas e 411 analyzer; modular analytics e 170 module; and cobas e 601, 602, and 801 modules with plasma samples.The following customer observations have been reported: 1.Discrepant results between serum and plasma samples from the same blood draw of a given patient: negative results (< cutoff) on serum and positive results on plasma samples.2.Discrepant concentrations obtained on plasma samples when comparing different reagent lots.Serum samples are not affected and do not require a workaround.It is strongly advised to use the elecsys anti-ccp assay with serum samples only for the affected lots.Roche is conducting an investigation into the reported issue and has determined that the elecsys anti-ccp assay is strongly affected by pre-analytical errors.The investigation has reproduced these findings when requirements for pre-analytical sample handling have not been met for plasma samples.Therefore, we would like to emphasize the importance of following the pre-analytical sample handling recommendations when processing samples (serum and plasma).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ELECSYS ANTI-CCP IMMUNOASSAY
Type of Device
ANTIBODIES, ANTI-CYCLIC CITRULLINATED PEPTIDE (CCP)
Manufacturer (Section D)
ROCHE DIAGNOSTICS
9115 hague road
indianapolis IN 46250 0457
MDR Report Key8776987
MDR Text Key150755763
Report Number1823260-2019-02505
Device Sequence Number1
Product Code NHX
Combination Product (y/n)N
PMA/PMN Number
K081338
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,u
Type of Report Initial,Followup
Report Date 08/14/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received07/10/2019
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date09/30/2019
Device Catalogue Number05031656190
Device Lot Number38915201
Was Device Available for Evaluation? Yes
Date Manufacturer Received06/20/2019
Is This a Reprocessed and Reused Single-Use Device? No
Removal/Correction Number1823260-07/16/19-007-C
Patient Sequence Number1
-
-